+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PET Radioactive Tracers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 359 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5913354
Description Jump to:
The global PET radioactive tracers market has witnessed remarkable expansion reaching a market value of US$ 999 million in 2024, according to a recent study. The market is projected to maintain its upward trajectory, potentially reaching a valuation of US$ 1700 million by the end of 2031.

Radiopharmaceuticals Revolutionize Medical Imaging

Radiopharmaceuticals, also known as radioactive tracers or radiotracers, play a crucial role in medical imaging by assisting in locating diseased areas before further treatment procedures. These tracers contain a small amount of a radioactive substance emitting radiation, which specialized imaging equipment like single-photon emission computed tomography (SPECT) and positron emission tomography (PET) scanners can detect.

Recent years have witnessed regulatory approvals for various radiopharmaceuticals by esteemed authorities such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). These groundbreaking products cater to a wide range of applications, including cancer imaging and therapy, neurological disorders, and cardiology.

Gallium-68 Takes Center Stage

Gallium-68 (68Ga) has emerged as a significant player in nuclear medicine, particularly in the diagnosis and assessment of prostate cancer. The development relies heavily on the integration of technological advancements and the introduction of a groundbreaking radiotracer, 68Ga-PSMA-11, pioneered by the University of Heidelberg. The market authorization of the first 68Ge/68Ga generator by German manufacturer Eckert & Ziegler has further facilitated the penetration of the 68Ga-PSMA-11 tracer for prostate cancer treatment.

Factors Driving Demand for PET Radioactive Tracers

  • Increasing Global Cancer Prevalence: Cancer, a complex disease requiring accurate diagnosis and effective treatment, has led to the growing demand for advanced imaging techniques like SPECT and PET, which rely on radiopharmaceuticals. The rising incidence of cancer worldwide is a significant driver for the PET radioactive tracers market.
  • Supply Chain Challenges: The reliance on imported radiopharmaceuticals in many countries can result in supply chain problems, delays, and increased costs. To overcome this, radiopharmaceutical manufacturers are focusing on domestic radioisotope production, ensuring a stable supply of products.
  • Investments in Domestic Production Facilities: Governments and private companies are investing in building domestic radiopharmaceutical production facilities. These initiatives not only ensure a stable supply but also create jobs, improve healthcare access, and enhance healthcare outcomes.

Challenges to Adoption

  • Limited Imaging Time: Radiopharmaceuticals have shorter half-lives, limiting imaging time. For certain imaging protocols requiring longer durations, such as some dynamic PET studies, this can pose challenges.
  • Availability in Clinical Settings: Radiopharmaceuticals with shorter half-lives may not be available in all clinical settings, limiting their use in some scenarios.

Country-wise Insights

United States: The U.S. dominates the North American PET radioactive tracers market, driven by the increasing utilization of PET scanning in oncology and neurology.

China: Significant investments in cyclotron facilities and radioactive tracer production capabilities have positioned China as a prominent market player, producing isotopes for medical imaging applications.

Germany: The burden of neurological disorders, including Alzheimer's and Parkinson's disease, in Germany has led to the growing use of PET-CT imaging in their diagnosis and management.

Competitive Landscape

The PET radioactive tracers market is characterized by a consolidated landscape with a few key players. Companies are actively expanding their presence in emerging markets, exploring strategic partnerships, acquisitions, and mergers to drive growth.

Key Companies in the Market:

  • Eli Lilly and Company
  • Blue Earth Diagnostics
  • Lantheus
  • Siemens Healthcare Private Limited
  • GE Healthcare
  • And more.

Key Segments of PET Radioactive Tracers Industry Research

Product:

  • F-18
  • Florbetapir
  • Florbetaben
  • Flutemetamol
  • Fludeoxyglucose
  • Sodium Fluoride
  • Others
  • C-11
  • Choline
  • Methionine
  • Others
  • Ga-68
  • DOTA-TOC
  • DOTATATE
  • DOTANOC
  • Others
  • O-15
  • N-13
  • Cu-64

Application:

  • Neurological Disorders
  • Alzheimer’s Disease
  • Dementia
  • Others
  • Cancer Diagnosis & Prognosis
  • Solid Tumors
  • Hematology Tumors
  • Cardiac Dysfunctions
  • Myocardial Infarction
  • Others
  • Infectious Disease Diagnosis
  • Others

End User:

  • Hospitals
  • Speciality Diagnostic Centers
  • Cancer Research Centers
  • Academic & Research Institutes

Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Western Europe
  • Eastern Europe
  • Central Asia
  • Russia & Belarus
  • Balkan & Baltic Countries
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global PET Radioactive Tracers Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global PET Radioactive Tracers Market Outlook, 2018 - 2031
3.1. Global PET Radioactive Tracers Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. F-18
3.1.1.1.1. Florbetapir
3.1.1.1.2. Florbetaben
3.1.1.1.3. Flutemetamol
3.1.1.1.4. Fludeoxyglucose
3.1.1.1.5. Sodium Fluoride
3.1.1.1.6. Others
3.1.1.2. C-11
3.1.1.2.1. Choline
3.1.1.2.2. Methionine
3.1.1.2.3. Others
3.1.1.3. Ga-68
3.1.1.3.1. DOTA-TOC
3.1.1.3.2. DOTATATE
3.1.1.3.3. DOTANOC
3.1.1.3.4. Others
3.1.1.4. O-15
3.1.1.5. N-13
3.1.1.6. Cu-64
3.2. Global PET Radioactive Tracers Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Neurological Disorders
3.2.1.1.1. Alzheimer’s Disease
3.2.1.1.2. Dementia
3.2.1.1.3. Others
3.2.1.2. Cancer Diagnosis & Prognosis
3.2.1.2.1. Solid Tumors
3.2.1.2.2. Hematology Tumors
3.2.1.3. Cardiac Dysfunctions
3.2.1.3.1. Myocardial Infarction
3.2.1.3.2. Others
3.2.1.4. Infectious Disease Diagnosis
3.2.1.5. Others
3.3. Global PET Radioactive Tracers Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Speciality Diagnostic Centers
3.3.1.3. Cancer Research Centers
3.3.1.4. Academic & Research Institutes
3.4. Global PET Radioactive Tracers Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America PET Radioactive Tracers Market Outlook, 2018 - 2031
4.1. North America PET Radioactive Tracers Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. F-18
4.1.1.1.1. Florbetapir
4.1.1.1.2. Florbetaben
4.1.1.1.3. Flutemetamol
4.1.1.1.4. Fludeoxyglucose
4.1.1.1.5. Sodium Fluoride
4.1.1.1.6. Others
4.1.1.2. C-11
4.1.1.2.1. Choline
4.1.1.2.2. Methionine
4.1.1.2.3. Others
4.1.1.3. Ga-68
4.1.1.3.1. DOTA-TOC
4.1.1.3.2. DOTATATE
4.1.1.3.3. DOTANOC
4.1.1.3.4. Others
4.1.1.4. O-15
4.1.1.5. N-13
4.1.1.6. Cu-64
4.2. North America PET Radioactive Tracers Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Neurological Disorders
4.2.1.1.1. Alzheimer’s Disease
4.2.1.1.2. Dementia
4.2.1.1.3. Others
4.2.1.2. Cancer Diagnosis & Prognosis
4.2.1.2.1. Solid Tumors
4.2.1.2.2. Hematology Tumors
4.2.1.3. Cardiac Dysfunctions
4.2.1.3.1. Myocardial Infarction
4.2.1.3.2. Others
4.2.1.4. Infectious Disease Diagnosis
4.2.1.5. Others
4.3. North America PET Radioactive Tracers Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospitals
4.3.1.2. Speciality Diagnostic Centers
4.3.1.3. Cancer Research Centers
4.3.1.4. Academic & Research Institutes
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America PET Radioactive Tracers Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe PET Radioactive Tracers Market Outlook, 2018 - 2031
5.1. Europe PET Radioactive Tracers Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. F-18
5.1.1.1.1. Florbetapir
5.1.1.1.2. Florbetaben
5.1.1.1.3. Flutemetamol
5.1.1.1.4. Fludeoxyglucose
5.1.1.1.5. Sodium Fluoride
5.1.1.1.6. Others
5.1.1.2. C-11
5.1.1.2.1. Choline
5.1.1.2.2. Methionine
5.1.1.2.3. Others
5.1.1.3. Ga-68
5.1.1.3.1. DOTA-TOC
5.1.1.3.2. DOTATATE
5.1.1.3.3. DOTANOC
5.1.1.3.4. Others
5.1.1.4. O-15
5.1.1.5. N-13
5.1.1.6. Cu-64
5.2. Europe PET Radioactive Tracers Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Neurological Disorders
5.2.1.1.1. Alzheimer’s Disease
5.2.1.1.2. Dementia
5.2.1.1.3. Others
5.2.1.2. Cancer Diagnosis & Prognosis
5.2.1.2.1. Solid Tumors
5.2.1.2.2. Hematology Tumors
5.2.1.3. Cardiac Dysfunctions
5.2.1.3.1. Myocardial Infarction
5.2.1.3.2. Others
5.2.1.4. Infectious Disease Diagnosis
5.2.1.5. Others
5.3. Europe PET Radioactive Tracers Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Speciality Diagnostic Centers
5.3.1.3. Cancer Research Centers
5.3.1.4. Academic & Research Institutes
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe PET Radioactive Tracers Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.7. France PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.8. France PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.9. France PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest of Europe PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest of Europe PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest of Europe PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific PET Radioactive Tracers Market Outlook, 2018 - 2031
6.1. Asia Pacific PET Radioactive Tracers Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. F-18
6.1.1.1.1. Florbetapir
6.1.1.1.2. Florbetaben
6.1.1.1.3. Flutemetamol
6.1.1.1.4. Fludeoxyglucose
6.1.1.1.5. Sodium Fluoride
6.1.1.1.6. Others
6.1.1.2. C-11
6.1.1.2.1. Choline
6.1.1.2.2. Methionine
6.1.1.2.3. Others
6.1.1.3. Ga-68
6.1.1.3.1. DOTA-TOC
6.1.1.3.2. DOTATATE
6.1.1.3.3. DOTANOC
6.1.1.3.4. Others
6.1.1.4. O-15
6.1.1.5. N-13
6.1.1.6. Cu-64
6.2. Asia Pacific PET Radioactive Tracers Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Neurological Disorders
6.2.1.1.1. Alzheimer’s Disease
6.2.1.1.2. Dementia
6.2.1.1.3. Others
6.2.1.2. Cancer Diagnosis & Prognosis
6.2.1.2.1. Solid Tumors
6.2.1.2.2. Hematology Tumors
6.2.1.3. Cardiac Dysfunctions
6.2.1.3.1. Myocardial Infarction
6.2.1.3.2. Others
6.2.1.4. Infectious Disease Diagnosis
6.2.1.5. Others
6.3. Asia Pacific PET Radioactive Tracers Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Speciality Diagnostic Centers
6.3.1.3. Cancer Research Centers
6.3.1.4. Academic & Research Institutes
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific PET Radioactive Tracers Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.2. China PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.3. China PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.10. India PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.11. India PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.12. India PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America PET Radioactive Tracers Market Outlook, 2018 - 2031
7.1. Latin America PET Radioactive Tracers Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. F-18
7.1.1.1.1. Florbetapir
7.1.1.1.2. Florbetaben
7.1.1.1.3. Flutemetamol
7.1.1.1.4. Fludeoxyglucose
7.1.1.1.5. Sodium Fluoride
7.1.1.1.6. Others
7.1.1.2. C-11
7.1.1.2.1. Choline
7.1.1.2.2. Methionine
7.1.1.2.3. Others
7.1.1.3. Ga-68
7.1.1.3.1. DOTA-TOC
7.1.1.3.2. DOTATATE
7.1.1.3.3. DOTANOC
7.1.1.3.4. Others
7.1.1.4. O-15
7.1.1.5. N-13
7.1.1.6. Cu-64
7.2. Latin America PET Radioactive Tracers Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
7.2.1.1. Neurological Disorders
7.2.1.1.1. Alzheimer’s Disease
7.2.1.1.2. Dementia
7.2.1.1.3. Others
7.2.1.2. Cancer Diagnosis & Prognosis
7.2.1.2.1. Solid Tumors
7.2.1.2.2. Hematology Tumors
7.2.1.3. Cardiac Dysfunctions
7.2.1.3.1. Myocardial Infarction
7.2.1.3.2. Others
7.2.1.4. Infectious Disease Diagnosis
7.2.1.5. Others
7.3. Latin America PET Radioactive Tracers Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Speciality Diagnostic Centers
7.3.1.3. Cancer Research Centers
7.3.1.4. Academic & Research Institutes
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America PET Radioactive Tracers Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest of Latin America PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest of Latin America PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest of Latin America PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa PET Radioactive Tracers Market Outlook, 2018 - 2031
8.1. Middle East & Africa PET Radioactive Tracers Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. F-18
8.1.1.1.1. Florbetapir
8.1.1.1.2. Florbetaben
8.1.1.1.3. Flutemetamol
8.1.1.1.4. Fludeoxyglucose
8.1.1.1.5. Sodium Fluoride
8.1.1.1.6. Others
8.1.1.2. C-11
8.1.1.2.1. Choline
8.1.1.2.2. Methionine
8.1.1.2.3. Others
8.1.1.3. Ga-68
8.1.1.3.1. DOTA-TOC
8.1.1.3.2. DOTATATE
8.1.1.3.3. DOTANOC
8.1.1.3.4. Others
8.1.1.4. O-15
8.1.1.5. N-13
8.1.1.6. Cu-64
8.2. Middle East & Africa PET Radioactive Tracers Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Neurological Disorders
8.2.1.1.1. Alzheimer’s Disease
8.2.1.1.2. Dementia
8.2.1.1.3. Others
8.2.1.2. Cancer Diagnosis & Prognosis
8.2.1.2.1. Solid Tumors
8.2.1.2.2. Hematology Tumors
8.2.1.3. Cardiac Dysfunctions
8.2.1.3.1. Myocardial Infarction
8.2.1.3.2. Others
8.2.1.4. Infectious Disease Diagnosis
8.2.1.5. Others
8.3. Middle East & Africa PET Radioactive Tracers Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Speciality Diagnostic Centers
8.3.1.3. Cancer Research Centers
8.3.1.4. Academic & Research Institutes
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa PET Radioactive Tracers Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa PET Radioactive Tracers Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa PET Radioactive Tracers Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa PET Radioactive Tracers Market by End User, Value (US$ Mn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Eli Lilly and Company
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Blue Earth Diagnostics
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Lantheus
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Siemens Healthcare Private Limited
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. GE Healthcare
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Advanced Accelerator Applications (Novartis)
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. University of Lowa HealthCare
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Eli Lilly and Company
  • Blue Earth Diagnostics
  • Lantheus
  • Siemens Healthcare Private Limited
  • GE Healthcare
  • Advanced Accelerator Applications (Novartis)
  • University of Lowa HealthCare
  • Telix Pharmaceuticals Limited
  • Jubilant Radiopharma
  • TRASIS
  • RadioMedix Inc.
  • IBA Radiopharma Solutions
  • Piramal Imaging (Life Molecular Imaging)
  • Cardinal Health
  • DuchemBio, Co., Ltd

Methodology

Loading
LOADING...

Related Topics

Related Reports

Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033 - Product Image

Nuclear Imaging Equipment Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033

  • Report
  • Global
From
Diagnostic Imaging Market Global Forecast Report By Product, Application, End User, Countries and Company Analysis 2024-2032 - Product Image

Diagnostic Imaging Market Global Forecast Report By Product, Application, End User, Countries and Company Analysis 2024-2032

  • Report
  • 210 Pages
  • Global
From
Nuclear Imaging Equipment Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product, Application, and End-user - Product Image

Nuclear Imaging Equipment Market Size and Forecasts 2020-2031: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product, Application, and End-user

  • Report
  • 117 Pages
  • Global
From
Nuclear Imaging Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Nuclear Imaging Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Nuclear Imaging Equipment Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update - Product Image

Nuclear Imaging Equipment Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.